Efrat Dotan, MD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497
Video: Efrat Dotan, MD
Colorectal Cancer Treatment at Fox Chase Cancer Center
Assistant Program Director,
Medical Oncology Fellowship Program
Meet other members of the
American Board of Internal Medicine,
Board certification in hematology and medical oncology
Early in my medical training I was drawn to the oncology field which combines compassionate patient care with cutting edge research. Once I completed my oncology training I elected to stay at Fox Chase Cancer Center where the combination of patient care and active research is a way of life. Furthermore, continued collaboration with the basic scientists at Fox Chase Cancer Center provides a perfect platform for development and testing of novel concepts in cancer management.
My research interests include evaluating new treatment targets and new treatment modalities that could potentially improve outcomes for patients with colorectal cancer and other gastrointestinal malignancies. In particular I am interested in the management and outcomes of elderly patients with cancer. Treatment of this patient population requires special consideration biologically, medically and socially. Due to the aging of our patient population, the field of geriatric oncology is rapidly growing. Continued research for identifying tumor characteristics that are specific to this population, and new treatment modalities that would be better tolerated by older individuals will have improve outcomes and quality of life of these patients.
MD, Technion, Israel Institute of Technology, Bruce Rappaport Faculty of Medicine, cum laude 2002
Chief Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2007;
Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2006
Chief Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
Honors and Awards
AMGEN fellowship grant 2009;
American College of Physician (ACP): Associate research competition award.
American Society of Clinical Oncology (ASCO);
International Society of Geriatric Oncology (SIOG);
Cancer and Aging Research Group (CARG);
Eastern Cooperative Oncology Group (ECOG);
American Medical Association (AMA)
Research InterestsPrinciple Investigator page
• Clinical trials of novel treatments for gastrointestinal cancers.
• Drug Development
• Clinical trial specific to older cancer patients.
PublicationsDr. Dotan On PubMed and My NCBI
- Vijayvergia N, Dotan E, Devarajan K, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center Experience. J Geriatr Oncol. 2015; S1879-4068. [Epub ahead of print].
- Dotan E, Li T, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. JOP. September 2014 10(5): 308-14.
- McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol, August 2014; 32: 2570-2580.
- Dotan E, Devarajan K, D’Silva JA, Beck A, Kloth D, Cohen J S, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies among older adults with metastatic colorectal cancer. Clinical Colorectal Cancer. September 2014; 13(3):192-8.
- Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55
- Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24
- Dotan E, Meropol J N, Burtness B, Denlinger C et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC340072
- Dotan E, Cohen S J. Challenges in the management of stage II colon cancer. Seminars in Oncology Aug 2011; 38(4): 511-20
- Dotan E, Cohen S J, Alpaugh K, Meropol N J. Circulating tumor cells: evolving evidence and future challenges. The oncologist, November 2009, 14(11): 1070-1082